REG - Ondine Biomedical - Notice of Results and Investor Presentation

Ondine BiomedicalAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260528:nRSb9533Fa&default-theme=true

RNS Number : 9533F  Ondine Biomedical Inc.  28 May 2026

28 May 2026

 

Ondine Biomedical Inc.

("Ondine" or the "Company")

Notice of Results and Investor Presentation

 

Ondine Biomedical Inc. (AIM: OBI) announces that it will publish its audited
results for the year ended 31 December 2025 ("Full Year Results") and Annual
Report 2025 on 4 June 2026.

 

Dr. Nicolas Loebel, President and Chief Technology Officer, and Alan Thomas,
Chief Financial Officer, will host a presentation and live Q&A session
relating to the Full Year Results via Investor Meet Company on 4 June 2026 at
16:30 BST (08:30 Pacific time).

 

The presentation is open to all sell-side analysts, existing and potential
shareholders. Questions can be submitted pre-event via your Investor Meet
Company dashboard up until 3 June 2026, 09:00 BST (01:00 Pacific time), or at
any time during the presentation.

 

Investors can sign up to Investor Meet Company for free and add to meet ONDINE
BIOMEDICAL INC. via:

 

https://www.investormeetcompany.com/ondine-biomedical-inc/register-investor
(https://www.investormeetcompany.com/ondine-biomedical-inc/register-investor)
 

 

Investors who already follow ONDINE BIOMEDICAL INC. on the Investor Meet
Company platform will automatically be invited.

 

A full overview of the 2025 fiscal year will be presented in the Annual Report
2025, which will be available on the Company's website on 4 June 2026 at:
www.ondinebio.com/investors/reports-documentation
(http://www.ondinebio.com/investors/reports-documentation) . The slides and
recording of the live presentation will be posted to the same webpage as soon
as available following the presentation, no later than 5 June 2026.

 

 

Enquiries:

 

 Ondine Biomedical Inc.                                www.ondinebio.com (http://www.ondinebio.com/)
 Carolyn Cross, CEO                                    +1 604 669 0555

 Strand Hanson Limited (Nominated & Joint Financial Adviser)
 James Harris, Richard Johnson                         +44 (0)20 7409 3494

 Peel Hunt LLP (Broker & Joint Financial Adviser)
 James Steel, Dr. Chris Golden                         +44 (0)20 7418 8900

 5654 & Company (Financial PR and IR Adviser)          ondinebiomedical@5654.co.uk
 Matthew Neal, Chris Gardner, Melissa Gardiner         +44 0791 7800 011

                                                       +44 0775 7697 357

 

 

About Ondine Biomedical Inc.

 

Ondine Biomedical Inc. is a Canadian life sciences company and leader in
light-activated antimicrobial therapies ('photodisinfection') for the
prevention and treatment of infections, including those caused by
multidrug-resistant organisms. Ondine has a pipeline of investigational
products, based on its proprietary photodisinfection technology, in various
stages of development.

 

Ondine's nasal photodisinfection system is CE-marked in Europe and is approved
for nasal decolonisation in Canada, Australia, Mexico, and several other
countries under the name Steriwave(®). In the US, it has been granted
Qualified Infectious Disease Product designation and Fast Track status by the
FDA and is currently undergoing clinical trials for regulatory approval.
Products beyond nasal photodisinfection include therapies for a variety of
medical indications such as chronic sinusitis, ventilator-associated
pneumonia, burns, and other indications.

 

U.S. Regulatory Status Disclaimer

Steriwave(®) is CE-marked in Europe and is approved for nasal decolonisation
in Canada, the United Kingdom, Australia, and Mexico. In the United States,
Steriwave has been granted Qualified Infectious Disease Product (QIDP)
designation and Fast Track status by the U.S. Food and Drug Administration
(FDA). It is currently undergoing clinical trials in the United States to
support regulatory approval and is limited by United States law to
investigational use only. It is not commercially available for sale or
clinical use in the United States.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORARMRTMTTTBAF



            Copyright 2019 Regulatory News Service, all rights reserved